These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 33127935)

  • 1. Clinical implication of oncogenic somatic mutations in early-stage cervical cancer with radical hysterectomy.
    Watanabe T; Nanamiya H; Kojima M; Nomura S; Furukawa S; Soeda S; Tanaka D; Isogai T; Imai JI; Watanabe S; Fujimori K
    Sci Rep; 2020 Oct; 10(1):18734. PubMed ID: 33127935
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Detection of oncogenic mutations in cervical carcinoma using method High Resolution Melting (HRM).
    Wayhelova M; Mikulasova A; Smetana J; Vallova V; Blazkova D; Filkova H; Moukova L; Kuglik P
    Neoplasma; 2016; 63(5):779-88. PubMed ID: 27468883
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Risk factors and prognosis of IB-IIB cervical carcinoma with common iliac lymph node metastasis.
    Huang L; Zheng M; Liu JH; Xiong Y; Ding H; Tang L; Wang HY
    Chin J Cancer; 2010 Apr; 29(4):431-5. PubMed ID: 20346221
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Precise Classification of Cervical Carcinomas Combined with Somatic Mutation Profiling Contributes to Predicting Disease Outcome.
    Spaans VM; Trietsch MD; Peters AA; Osse M; Ter Haar N; Fleuren GJ; Jordanova ES
    PLoS One; 2015; 10(7):e0133670. PubMed ID: 26197069
    [TBL] [Abstract][Full Text] [Related]  

  • 5. ERBB2 mutation: A promising target in non-squamous cervical cancer.
    Xiang L; Jiang W; Ye S; He T; Pei X; Li J; Chan DW; Ngan HYS; Li F; Tao P; Shen X; Zhou X; Wu X; Yang G; Yang H
    Gynecol Oncol; 2018 Feb; 148(2):311-316. PubMed ID: 29279289
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Multivariate analysis of histopathologic prognostic factors for invasive cervical cancer treated with radical hysterectomy and systematic retroperitoneal lymphadenectomy.
    Takeda N; Sakuragi N; Takeda M; Okamoto K; Kuwabara M; Negishi H; Oikawa M; Yamamoto R; Yamada H; Fujimoto S
    Acta Obstet Gynecol Scand; 2002 Dec; 81(12):1144-51. PubMed ID: 12519111
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Survival of women with microinvasive adenocarcinoma of the cervix is not improved by radical surgery.
    Bean LM; Ward KK; Plaxe SC; McHale MT
    Am J Obstet Gynecol; 2017 Sep; 217(3):332.e1-332.e6. PubMed ID: 28522318
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficient mutation screening for cervical cancers from circulating tumor DNA in blood.
    Lee SY; Chae DK; Lee SH; Lim Y; An J; Chae CH; Kim BC; Bhak J; Bolser D; Cho DH
    BMC Cancer; 2020 Jul; 20(1):694. PubMed ID: 32718341
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Can pelvic lymphadenectomy be omitted in stage IA2 to IIB uterine cervical cancer?
    Togami S; Kamio M; Yanazume S; Yoshinaga M; Douchi T
    Int J Gynecol Cancer; 2014 Jul; 24(6):1072-6. PubMed ID: 24905616
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Radical hysterectomy for FIGO stage IIB cervical cancer: clinicopathological characteristics and prognostic evaluation.
    Kasamatsu T; Onda T; Sawada M; Kato T; Ikeda S
    Gynecol Oncol; 2009 Jul; 114(1):69-74. PubMed ID: 19398126
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Distribution of genetic alterations in high-risk early-stage cervical cancer patients treated with postoperative radiation therapy.
    Murakami N; Asami Y; Yoshida H; Takayanagi D; Hirose S; Kuno I; Takahashi K; Matsuda M; Shimada Y; Yamano S; Sunami K; Honda T; Nakahara T; Watanabe T; Okuma K; Kuroda T; Kohno T; Kato T; Shiraishi K; Itami J
    Sci Rep; 2021 May; 11(1):10567. PubMed ID: 34012039
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Analysis of KRAS, NRAS, BRAF, PIK3CA and TP53 mutations in a large prospective series of locally advanced rectal cancer patients.
    Sclafani F; Wilson SH; Cunningham D; Gonzalez De Castro D; Kalaitzaki E; Begum R; Wotherspoon A; Capdevila J; Glimelius B; Roselló S; Thomas J; Tait D; Brown G; Oates J; Chau I
    Int J Cancer; 2020 Jan; 146(1):94-102. PubMed ID: 31199501
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mutational profiles of marker genes of cervical carcinoma in Bangladeshi patients.
    Sharmin S; Zohura FT; Islam MS; Shimonty A; Khan MA; Parveen R; Sharmin F; Ahsan CR; Islam ABMMK; Yasmin M
    BMC Cancer; 2021 Mar; 21(1):289. PubMed ID: 33736612
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognosis and clinicopathological characteristics of Ib-IIb adenocarcinoma of the uterine cervix in patients who have had radical hysterectomy.
    Irie T; Kigawa J; Minagawa Y; Itamochi H; Sato S; Akeshima R; Terakawa N
    Eur J Surg Oncol; 2000 Aug; 26(5):464-7. PubMed ID: 11016467
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Influence of lymph vascular space invasion on prognosis of patients with early-stage cervical squamous cell carcinoma.
    Yan M; Zhang YN; He JH; Sun JR; Sun XM
    Chin J Cancer; 2010 Apr; 29(4):425-30. PubMed ID: 20346220
    [TBL] [Abstract][Full Text] [Related]  

  • 16. TP53 and PIK3CA gene mutations in adenocarcinoma, squamous cell carcinoma and high-grade intraepithelial neoplasia of the cervix.
    Tornesello ML; Annunziata C; Buonaguro L; Losito S; Greggi S; Buonaguro FM
    J Transl Med; 2014 Sep; 12():255. PubMed ID: 25220666
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Lymphatic mapping and parametrial lymph nodes identification in patients with early stage cervical cancer].
    Li B; Wu LY; Li XG; Zhang X; Zhang WH; Gao JZ
    Zhonghua Fu Chan Ke Za Zhi; 2006 Sep; 41(9):608-11. PubMed ID: 17181971
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeted sequencing reveals TP53 as a potential diagnostic biomarker in the post-treatment surveillance of head and neck cancer.
    van Ginkel JH; de Leng WW; de Bree R; van Es RJ; Willems SM
    Oncotarget; 2016 Sep; 7(38):61575-61586. PubMed ID: 27528217
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clusterin expression predicts survival of invasive cervical cancer patients treated with radical hysterectomy and systematic lymphadenectomy.
    Watari H; Ohta Y; Hassan MK; Xiong Y; Tanaka S; Sakuragi N
    Gynecol Oncol; 2008 Mar; 108(3):527-32. PubMed ID: 18177691
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic factors in stage IB-IIB cervical adenocarcinoma patients treated with radical hysterectomy and pelvic lymphadenectomy.
    Kodama J; Seki N; Masahiro S; Kusumoto T; Nakamura K; Hongo A; Hiramatsu Y
    J Surg Oncol; 2010 Apr; 101(5):413-7. PubMed ID: 20127891
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.